Periodontal bacteria enhance oral KSHV pathogenesis and Kaposi's Sarcoma development in HIV + patients
牙周细菌增强 HIV 患者口腔 KSHV 发病机制和卡波西肉瘤的发展
基本信息
- 批准号:10613370
- 负责人:
- 金额:$ 32.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAnti-HIV TherapyAntibioticsAntioxidantsBacteriaBiologicalCell Culture TechniquesCellsClinicalClinical DataClinical ResearchClinical TrialsCommon NeoplasmConditioned Culture MediaCyclin D1DataDevelopmentEnvironmentEtiologyHIVHIV InfectionsHIV/AIDSHeparan Sulfate ProteoglycanHerpesviridae InfectionsHigh PrevalenceHumanHuman Herpesvirus 8Immunocompromised HostImmunosuppressionIncidenceIncubatedInfectionInflammationKaposi SarcomaLinkLipopolysaccharidesLyticMaintenanceMethodsMicroRNAsMolecularMorbidity - disease rateMouth NeoplasmsOncogenic VirusesOralOral cavityPalate Kaposi&aposs SarcomaPathogenesisPatientsPatternPeriodontal DiseasesPlasmaPorphyromonas gingivalisPreventionPreventiveProductionPublishingReactive Oxygen SpeciesRegulationRiskRoleSalivaSalivarySamplingStaphylococcus aureusStructureTLR2 geneTimeTumor TissueViralViral PathogenesisViral ProteinsVirusVirus LatencyVirus Sheddingclinical developmentclinically relevantco-infectioncofactorcohortinfection rateinnovationinsightlatent gene expressionlipoteichoic acidmortalitynoveloral fibroblastoral microbiomepathogenpathogenic bacteriapreventprotein expressionreactivation from latencyreceptortherapeutic targettransmission processtumortumorigenesisvirus related cancer
项目摘要
PROJECT ABSTRACT
Kaposi's sarcoma (KS) remains the most common tumor arising in patients with HIV/AIDS, and involvement of
the oral cavity represents one of the most common clinical manifestations of this tumor. HIV infection incurs an
increased risk for periodontal diseases and oral carriage from a variety of pathogenic bacteria. However,
whether interactions involving periodontal bacteria and oncogenic viruses in the local environment facilitate
replication or maintenance of these viruses in the oral cavity remains largely unknown. Our published and
preliminary data indicate that incubation of human primary oral cells with two prototypical pathogen-associated
molecular patterns (PAMPs) produced by prominent periodontal bacteria—lipoteichoic acid (LTA) from
Staphylococcus aureus (Sa) and lipopolysaccharide (LPS) from Porphyromonas gingivalis (Pg)—increases
initial viral entry and subsequent latent gene expression during de novo KSHV infection. Moreover, LTA and
LPS up-regulate one of cellular receptors for KSHV entry, Heparan sulfate proteoglycan (HSPG) and increase
reactive oxygen species (ROS) production as co-factor contributed to KSHV infection. Additionally, we found
that conditioned medium from Sa and Pg culture or bacterial PAMPs induced viral lytic reactivation from
latently infected oral cells through regulation of viral microRNAs expression, promoting virus dissemination. For
clinical relevance, we found a high infection and co-infection rate of Sa, Pg and KSHV in the oral cavity of our
cohort of HIV+ patients, and found higher levels of salivary ROS, host antioxidant factors and bacterial
LTA/LPS from HIV+/KSHV+ patients than those HIV+/KSHV- ones. Based on these data, we hypothesize that
periodontal bacteria or their PAMPs may facilitate initial KSHV infection, replication and dissemination
in the oral cavity of HIV+ patients through multiple host and viral factors, and ultimately promote oral
KS development. To address this hypothesis, we propose the following specific aims including both clinical
and basic studies: 1) Determine the clinical relevance and correlations between host salivary antioxidant
factors, specific bacterial carriage/PAMPs levels, and KSHV oral shedding in HIV+ patients. 2) Identify the
mechanisms through which periodontal bacteria or their PAMPs facilitate KSHV initial infection and viral lytic
reactivation, two important steps necessary for KS development. Through these efforts, we can better
understand how pathogens co-infection can promote virus-associated cancer development in oral unique niche
of immunocompromised patients. Our results will also provide the framework for the development of clinical
trials evaluating the strategies interfering with host-bacteria-virus interaction (e.g. specific antibiotics, targeting
TLRs-ROS axis or viral microRNAs synthesis) for their abilities to reduce or prevent oral KSHV infection and
KS progression in HIV+ patients.
项目摘要
项目成果
期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus.
- DOI:10.1038/s42003-021-02220-z
- 发表时间:2021-06-03
- 期刊:
- 影响因子:5.9
- 作者:Chen J;Dai L;Barrett L;James J;Plaisance-Bonstaff K;Post SR;Qin Z
- 通讯作者:Qin Z
Activation of IL1 signaling molecules by Kaposi's sarcoma-associated herpesvirus.
- DOI:10.3389/fcimb.2022.1049624
- 发表时间:2022
- 期刊:
- 影响因子:5.7
- 作者:
- 通讯作者:
The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways.
- DOI:10.1128/aac.02395-21
- 发表时间:2022-03-15
- 期刊:
- 影响因子:4.9
- 作者:Chen J;Dai L;Kendrick S;Post SR;Qin Z
- 通讯作者:Qin Z
Porphyromonas gingivalis coinfects with KSHV in oral cavities of HIV+ patients and induces viral lytic reactivation.
牙龈卟啉单胞菌与HIV+患者口腔中的KSHV共感染,并诱导病毒裂解再活化。
- DOI:10.1002/jmv.26028
- 发表时间:2020-12
- 期刊:
- 影响因子:12.7
- 作者:Dai L;Barrett L;Plaisance-Bonstaff K;Post SR;Qin Z
- 通讯作者:Qin Z
The potential impacts of early secreted antigenic target of 6 kDa of Mycobacterium tuberculosis on KSHV-infected cells.
- DOI:10.1002/jmv.26291
- 发表时间:2021-06
- 期刊:
- 影响因子:12.7
- 作者:Dai L;Jung BG;Chen J;Samten B;Forrest JC;Post SR;Qin Z
- 通讯作者:Qin Z
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James Craig Forrest其他文献
James Craig Forrest的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James Craig Forrest', 18)}}的其他基金
Defining mechanisms of KSHV pathogenesis using MHV68-KSHV chimeric viruses
使用 MHV68-KSHV 嵌合病毒定义 KSHV 发病机制
- 批准号:
10243300 - 财政年份:2020
- 资助金额:
$ 32.46万 - 项目类别:
Periodontal bacteria enhance oral KSHV pathogenesis and Kaposi's Sarcoma development in HIV + patients
牙周细菌增强 HIV 患者口腔 KSHV 发病机制和卡波西肉瘤的发展
- 批准号:
10015211 - 财政年份:2019
- 资助金额:
$ 32.46万 - 项目类别:
Periodontal bacteria enhance oral KSHV pathogenesis and Kaposi's Sarcoma development in HIV + patients
牙周细菌增强 HIV 患者口腔 KSHV 发病机制和卡波西肉瘤的发展
- 批准号:
10400690 - 财政年份:2019
- 资助金额:
$ 32.46万 - 项目类别:
Defining mechanisms of gammaherpesvirus-driven genomic instability in B cells
定义 B 细胞中伽马疱疹病毒驱动的基因组不稳定性的机制
- 批准号:
10467371 - 财政年份:2014
- 资助金额:
$ 32.46万 - 项目类别:
Defining mechanisms of gammaherpesvirus-driven genomic instability in B cells
定义 B 细胞中伽马疱疹病毒驱动的基因组不稳定性的机制
- 批准号:
10590669 - 财政年份:2014
- 资助金额:
$ 32.46万 - 项目类别:
Defining mechanisms of gammaherpesvirus-driven genomic instability in B cells
定义 B 细胞中伽马疱疹病毒驱动的基因组不稳定性的机制
- 批准号:
10747707 - 财政年份:2014
- 资助金额:
$ 32.46万 - 项目类别:
Gammaherpesvirus interactions with host tumor suppressor p53
伽马疱疹病毒与宿主肿瘤抑制因子 p53 的相互作用
- 批准号:
9213350 - 财政年份:2014
- 资助金额:
$ 32.46万 - 项目类别:
Gammaherpesvirus interactions with host tumor suppressor p53
伽马疱疹病毒与宿主肿瘤抑制因子 p53 的相互作用
- 批准号:
8696558 - 财政年份:2014
- 资助金额:
$ 32.46万 - 项目类别:
DETERMINANTS OF CHRONIC GAMMAHERPESVIRUS 68 INFECTION
慢性丙型疱疹病毒 68 感染的决定因素
- 批准号:
7349299 - 财政年份:2006
- 资助金额:
$ 32.46万 - 项目类别:
Project 1 - Virus-Host Interactions in Gammaherpesvirus Pathogenesis
项目 1 - 伽玛疱疹病毒发病机制中的病毒-宿主相互作用
- 批准号:
8652484 - 财政年份:
- 资助金额:
$ 32.46万 - 项目类别:
相似海外基金
Pediatric Immune Correlates of Early Anti-HIV Therapy
早期抗 HIV 治疗的儿科免疫相关性
- 批准号:
8049900 - 财政年份:2010
- 资助金额:
$ 32.46万 - 项目类别:
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy
靶向 PI3K/Akt 细胞生存途径作为新型抗 HIV 疗法
- 批准号:
8006433 - 财政年份:2009
- 资助金额:
$ 32.46万 - 项目类别:
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy
靶向 PI3K/Akt 细胞生存途径作为新型抗 HIV 疗法
- 批准号:
8204745 - 财政年份:2009
- 资助金额:
$ 32.46万 - 项目类别:
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy
靶向 PI3K/Akt 细胞生存途径作为新型抗 HIV 疗法
- 批准号:
7743007 - 财政年份:2009
- 资助金额:
$ 32.46万 - 项目类别:
Targeting PI3K/Akt Cell Survival Pathway as a Novel Anti-HIV Therapy
靶向 PI3K/Akt 细胞生存途径作为新型抗 HIV 疗法
- 批准号:
7622243 - 财政年份:2009
- 资助金额:
$ 32.46万 - 项目类别:
Analysis of within-patient HIV-1 evolution and drug resistance mechanismsunder anti-HIV therapy
抗HIV治疗下患者体内HIV-1进化及耐药机制分析
- 批准号:
19510208 - 财政年份:2007
- 资助金额:
$ 32.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
From Total Synthesis-Inspired Methodology to Anti-HIV therapy
从全合成启发的方法到抗 HIV 治疗
- 批准号:
EP/E055273/1 - 财政年份:2007
- 资助金额:
$ 32.46万 - 项目类别:
Fellowship
Pediatric Immune Correlates of Early Anti-HIV Therapy
早期抗 HIV 治疗的儿科免疫相关性
- 批准号:
7187354 - 财政年份:2005
- 资助金额:
$ 32.46万 - 项目类别:
Establishment of Rev based anti-HIV therapy.
建立基于 Rev 的抗 HIV 疗法。
- 批准号:
17591037 - 财政年份:2005
- 资助金额:
$ 32.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Pediatric Immune Correlates of Early Anti-HIV Therapy
早期抗 HIV 治疗的儿科免疫相关性
- 批准号:
6843339 - 财政年份:2005
- 资助金额:
$ 32.46万 - 项目类别:














{{item.name}}会员




